Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

DRUGS > Cancer Drugs Classes/Targets > Flashcards

Cancer Drugs Classes/Targets Flashcards

1
Q

Osimertinib

A
  • Kinase-i
  • EGFR-i (inhibits T790M mutation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

BlinatumUmab

A
  • Bispecific antibody (T cell Engager) (BiTE)
  • binds CD3 to CD19
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tucatinib

A
  • Kinase-i
  • HER2-i &TKI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

M Phase

A

Microtubule-i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Alectinib

A
  • Kinase-i
  • EML4-ALK-i
  • genetic testing for mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cyclophosphamide

A
  • Alkylator
  • Prodrug –> phosphoramide mustard (PM)
  • Add Mesna to decrease acrolein (byproduct)
  • D-L: Hemorrhagic cystitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Midostaurin

A
  • Kinase-i
  • FLT3-i (broad)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Methotrexate

A
  • Antifolate
  • DHFR-i (inhibits TMP synthesis)
  • RM: inc. DHFR and dec. polyglutamation
  • Rescue: Leucovorin (rescues toxic effects)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bortezomib

A
  • Proteasome-i
  • SE: neuropathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Abiraterone

A
  • Endocrine
    -17alpha-hydrolase and C17,20 lyase-i
  • SE: inc. cholesterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

6-Mercaptopurine (6-MP)

A
  • Antimetabolite
  • Purine analog (inhibits purine synthesis)
  • RM: loss of HGPRT (activating enzyme)
  • inactivated by TPMT
  • DrugI: Allopurinol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Fulvestrant

A
  • Endocrine
  • SERD (selective estrogen receptor down-modulator)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Leuprolide

A
  • Endocrine
  • GnRH Analog
  • SE: gynecomastia, sex dysfxn
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PembroliZUmab

A
  • Antibody
  • targets PD-1 (blocks interaction with PD-L1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cytarabine (Ara-C)

A
  • Antimetabolite
  • Cytosine Analog (inhibits DNA polymerase)
  • Prodrug –> Ara-CTP
  • RM: inc. cytidine deaminase (CDA)
  • Synergy: Tethrahydrouridine (CDA-i)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Gefitinib

A
  • Kinase-i
  • EGFR-i (Exon 19 or 21) (L858R)
  • RM: T790M mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

G2 Phase

A
  • Top2-i (Etoposide and Bleomycin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CAR-T

A
  • Cell-based Tx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Venetoclax

A
  • Anti-Apoptotic protein-i
  • BCL-2-i
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

RituXImab

A
  • Antibody
  • targets CD20 (B cell/ Non-Hodgkin’s)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CetuXImab

A
  • Antibody
  • EGF-i
  • SEVERE infusion rxn
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Imatinib

A
  • Kinase-i
  • Bcr-Abl-i
  • RM: T3151 mutation
  • Tox: fluid retention and edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Sipulcel-T (Provenge)

A
  • Cell-Based Tx
  • PAP-GM-CSF
  • “Therapeutic Vaccine”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

G1 Phase

A
  • CDK4/6-i
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

TrastuZUmab

A
  • Antibody
  • targets HER2
  • combo with Pertu and Docetaxel
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

TrastuZUmab Emtansine

A
  • Antibody-drug conjugate
  • HER2 antibody
  • microtubule destabilizer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Letrozole

A
  • Endocrine
  • Aromatase-i (non-steroidal)
28
Q

Enzalutamide

A
  • Endocrine
  • Androgen Receptor Antagonist
29
Q

Erubulin

A
  • Microtubule-i
  • microtubule polymerization-i (destabilizer)
  • Lower rate of neurotoxicity than Vinca Alkaloids)
30
Q

PertuZUmab

A
  • Antibody
  • targerts HER2 (prevents dimerization)
  • combo with Trastu and Docetaxel
31
Q

Taquetamab

A
  • Bispecific antibody (T cell Engager) (BiTE)
  • binds CD3 with GPRC5D
32
Q

Ponatinib

A
  • Kinase-i
  • Bcr-Abl-i (inhibits T3151 mutation)
33
Q

Cisplatin

A
  • Platinum Compound
  • Prodrug –> Aquo form
  • D-L: Nephrotoxicity (proximal tubule)
34
Q

Teclistamab

A
  • Bispecific antibody (T cell Engager) (BiTE)
  • binds CD3 with BCMA (B cell maturation antigen)
35
Q

Lapatinib

A
  • Kinase-i
  • EGFR-i & HER2-i
  • SE: reversible dec. in cardiac function
36
Q

Doxorubicin

A
  • Top2-1
  • intercalates (free radicals)
  • SE: cardiotoxicity (iron-catalyzed free radical formation), extravasation
  • add Dexrazoxane to dec. cardiotoxicity
37
Q

S phase

A
  • Anti-Metabolites
  • Anti-Folates
  • Top1-i
38
Q

Non-Cell Cycle Specific

A
  • Alkylators
  • Platinum Compounds
  • Top2-i (Doxorubicin)
39
Q

5-Azacytosine

A
  • DNA Methylation-i
  • DNMT-i (reactivation of tumor suppressor genes)
40
Q

Olaparib

A
  • Kinase-1
  • PARP-i (traps PARP to DNA)
  • need BRCA mutation for PARP-i to work (BRCA is a tumor suppressor)
  • “synthetic lethality”
41
Q

Afatinib

A
  • Kinase-i
  • Covalent EGFR-i (Exon 19 or 21)
  • RM: T790M mutation
  • genetic test for mutation
42
Q

Paclitaxel

A
  • Microtubule-i (taxane)
  • Microtubule stabilizer
  • D-L: myelosuppresion
  • Linked to albumin
43
Q

Exemestane

A
  • Endocrine
  • Aromatase-i (steroidal)
44
Q

Vincristine

A
  • Microtubule-i (Vinca Alkaloid)
  • Microtubule Destabilizers
  • D-L: neurotoxicity
  • SE: extravasation
  • Rm: pGP
45
Q

Quizartinib

A
  • Kinase-i
  • FLT3-i (ITD mutation)
46
Q

DaratumUmab

A
  • Antibody
  • targets CD 38 (plasma B cell)
47
Q

Pomalidomide

A
  • thalidomide analog
  • degrades IKZF TFs
  • Needs POMALYST and REMS
48
Q

Etoposide

A
  • Top2-i
  • doesn’t intercalate (no free radicals)
49
Q

Acalabrutinib

A
  • Kinase-i
  • BTK-i
50
Q

Dabrafenib

A
  • Kinase-i
  • BRAF-V600-i
  • Combo with Trametinib (b/c Dabraf induces squamous cell carcinomas)
51
Q

Sirolimus

A
  • Kinase-i
  • Rapamycin Analog (mTOR-i) (blocks IL-2 signaling)
52
Q

Irinotecan

A
  • Top1-i
  • RM: pGP, MRP, GST
53
Q

AtezoliZUmab

A
  • Antibody
  • binds PD-L1 (blocks interaction with PD-1)
54
Q

Bleomycin

A
  • glycopeptide antibiotic (Top2-i)
  • free radicals cause DNA breaks
  • SE: Pulmonary toxicity and Rash (low levels of bleo aminohydrolase in skin and lungs)
  • RM: inc. bleo aminohydrolase
55
Q

MosunetuZUmab

A
  • Bispecific antibody (T cell Engager) (BiTE)
  • binds CD3 with
    CD20
  • D-L: cytokine storm
56
Q

Mitomycin C

A
  • Alkylator
  • D-L: myelosuppression
57
Q

RamucirUmab

A
  • Antibody
  • VGEF-i (binds receptor)
58
Q

Tamoxifen

A
  • Endocrine
  • SERM (selective estrogen receptor modulator)
  • Prodrug (CYP2D6)
59
Q

Palbociclib

A
  • Kinase-i
  • CDK4/6-i (stops phosphorylation of Rb)
  • involved in cell-cycle control
60
Q

TrastuZUmab Deruxtecan

A
  • Antibody-drug conjugate
  • HER2 antibody
  • Top1-i
61
Q

BevaciZUmab

A
  • Antibody
  • VGEF-i (binds ligand)
62
Q

5-FU

A
  • Antimetabolite
  • Uridine Analog (inhibit thymidylate synthase)
  • Prodrug –> FdUMP
  • RM: dec. of enzyme that 5-FU-> FdUMP
  • Rescue: Thymidine
  • Synergy: Leucovorin
  • metabolized by DPD
63
Q

IpilimUmab

A
  • Antibody
  • targets CTLA-4 (Remove Emergency breaks) (reverses CTL inhibition)
  • SE: inflammatory response (may need high-dose corticosteroid)
64
Q

Ixabepilone

A
  • Microtubule-i (Epothilones)
  • Microtubule stabilizers
65
Q

Chlorambucil

A
  • Alkylator
66
Q

Trametinib

A
  • Kinase-i
  • MEK1 & MEK2-i
  • can’t use if pt already received BRAF-i Tx
67
Q

Crenolanib

A
  • Kinase-i
  • FLT3-i (more specific)

DRUGS (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions